BrainChild Bio, Inc.
PrivateLast Round
Grant
Jan 21, 2025
Total Funding Raised
$300,000
Company Overview
BrainChild Bio, Inc. is a biotechnology company that develops CAR T-cell therapies for the treatment of pediatric and adult central nervous system tumors.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
BrainChild Bio, Inc. Comparables
Compare BrainChild Bio, Inc. with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Cellevolve Bio | 83% | |
| T-MAXIMUM Pharmaceutical | 79% | |
| Chimeric Therapeutics Limited | 78% | |
BrainChild Bio, Inc. Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Grant | Jan 21, 2025 | ||||
| Seed | Dec 5, 2023 |
Key People
Founding team and executive leadership
Market signals
Structured signals derived from secondary market and firmographic data.
- Apr 17, 2026
Monthly visitors increased 85% MoM.
- Jan 20, 2026
Monthly visitors increased 96% MoM.
BrainChild Bio, Inc. Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about BrainChild Bio, Inc.'s valuation, stock price, and market status.